Efficacy of erlotinib in subsequent lines of non‑small cell lung cancer therapy

01/2018

MUDr. Jana Krejčí, MUDr. Daniel Krejčí, doc. MUDr. Norbert Pauk, Ph.D.

Klinika pneumologie a hrudní chirurgie, Nemocnice Na Bulovce a 3. LF UK Praha

SUMMARY

Targeted therapy is becoming more and more important part of bronchial carcinoma treatment. One of the approaches includes administering erlotinib in later lines of therapy of non-small cell carcinoma. Our two case studies document a very good therapeutical effect as well as minimal toxicity of such an approach when treating adenocarcinoma (EGFR wild-type) and/or squamous carcinoma.

KEY WORDS

non-small cell lung carcinoma, targeted treatment, erlotinib